C

CT Clinical Research | Cromwell, CT

Research site

(Unclaimed)

Location

160 West Street, Suite 1A, Cromwell, Connecticut, United States of America

Site insights

Top conditions

Top treatments

JZP150

BI 1569912

Cariprazine

Dasotraline

Pimavanserin

Zavegepant

BHV-3500

Quetiapine

Simufilam

BI 1358894

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 15 total trials

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling

Depressive Disorder, Major

Drug: BI 1569912

Drug: Placebo

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling

Acute Treatment of Migraine

Drug: Rimegepant / BHV3000

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling

Pediatric Migraine

Drug: Rimegepant/BHV3000

Drug: Matching placebo

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: Simufilam